Apogee Therapeutics Inc. [APGE] stock is trading at $42.19, up 5.16%. An important factor to consider is whether the stock is rising or falling in short-term value. The APGE shares have gain 10.42% over the last week, with a monthly amount glided 1.20%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Apogee Therapeutics Inc. [NASDAQ: APGE] stock has seen the most recent analyst activity on May 10, 2024, when BofA Securities initiated its Buy rating and assigned the stock a price target of $80. Previously, BTIG Research started tracking the stock with Buy rating on December 20, 2023, and set its price target to $43. On August 08, 2023, Wedbush initiated with a Outperform rating and assigned a price target of $40 on the stock. TD Cowen started tracking the stock assigning a Outperform rating. Stifel initiated its recommendation with a Buy and recommended $34 as its price target on August 08, 2023. Jefferies started tracking with a Buy rating for this stock on August 08, 2023, and assigned it a price target of $29. In a note dated August 08, 2023, Guggenheim initiated an Buy rating and provided a target price of $29 on this stock.
Apogee Therapeutics Inc. [APGE] stock has fluctuated between $14.19 and $72.29 over the past year. Currently, Wall Street analysts expect the stock to reach $95 within the next 12 months. Apogee Therapeutics Inc. [NASDAQ: APGE] shares were valued at $42.19 at the most recent close of the market. An investor can expect a potential return of 125.17% based on the average APGE price forecast.
Analyzing the APGE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is -0.26 and Total Capital is -0.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 40.32 points at the first support level, and at 38.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 44.10, and for the 2nd resistance point, it is at 46.00.
Ratios To Look Out For
For context, Apogee Therapeutics Inc.’s Current Ratio is 38.08. On the other hand, the Quick Ratio is 38.08, and the Cash Ratio is 22.53.
Transactions by insiders
Recent insider trading involved HENDERSON MICHAEL THOMAS, Chief Executive Officer, that happened on Jul 05 ’24 when 15000.0 shares were sold. Chief Medical Officer, Dambkowski Carl completed a deal on Jul 03 ’24 to sell 5995.0 shares. Meanwhile, Director Fairmount Funds Management LLC bought 2.94 million shares on Jul 13 ’23.
